Orthogonal identification means confirming what a peptide is with two or more independent methods that measure different properties. An HPLC retention time and a purity percentage describe how a sample behaved on one column. They do not prove which molecule it is.
A certificate that pairs chromatography with mass spectrometry, and with further methods where the sequence calls for them, gives far stronger evidence of identity than any single number can.
This guide to orthogonal identification explains what each common method measures, why one method can miss what another catches, and what to look for on a certificate of analysis. It belongs to the glossary and reference material in the article library, which defines lab terms in ordinary language.
It describes analytical chemistry only. Identity and purity data say nothing about biological activity or suitability for any use.
What orthogonal identification means in a lab
In analytical chemistry, two methods are orthogonal when they rely on different physical or chemical properties, so the weakness of one is unlikely to be shared by the other. Chromatography separates molecules by how they interact with a column. Mass spectrometry measures their mass. Amino acid analysis measures what they are built from. That agreement is the point of orthogonal identification: it is much harder to reach by accident than a result from any one method.
Retention time
How long a compound takes to pass through an HPLC column. It depends on the column, solvents, gradient and temperature, so it is a property of the method as much as of the molecule.
Isobaric
Having the same mass. Leucine and isoleucine are isobaric, so a peptide with one swapped for the other weighs the same and a simple mass check cannot tell them apart.
Purity and content
Purity is the share of the chromatogram taken by the main peak. Peptide content is how much of the powder by weight is peptide at all, once water and salts are counted.
What a single HPLC result can and cannot show
Reversed-phase HPLC is the workhorse of peptide testing, and for good reason. It shows how many components a sample contains and how large the main peak is relative to the rest. What it cannot do on its own is say what the main peak is.
- Different molecules can share a retention time. Under one set of conditions, an impurity or a closely related sequence can elute alongside the target.
- A high purity figure can describe the wrong peptide. A sample can be 99% one compound and still not be the compound on the label.
- Retention time only means something against a reference. It is a comparison with a standard run on the same method, not an identity test by itself.
A review from the United States Pharmacopeia by McCarthy and colleagues (2023, Pharmaceutical Research) describes how peptide reference standards are characterised. Identity is tested with NMR, mass spectrometry and chromatography together, while HPLC and gas chromatography are used for content and impurities. The authors note that some peptide features, such as chiral or isobaric amino acids, may need additional techniques for full characterisation.
Orthogonal identification methods compared
Mass spectrometry
Mass spectrometry measures the mass of the intact molecule, usually as LC-MS, where chromatography feeds directly into the mass spectrometer. A result that matches the calculated mass of the sequence is strong evidence the right peptide is present. It also reveals truncated sequences, missing residues and added groups as mass shifts.
Tandem mass spectrometry (MS/MS)
MS/MS breaks the peptide into fragments and measures those too. Because fragments follow the order of the amino acids, the pattern supports the sequence itself, not just the total mass. The TB-500 metabolite study described in our TB-500 profile used this kind of method to measure the parent peptide and its shorter pieces, such as Ac-LK and Ac-LKK, at the same time.
Amino acid analysis
The peptide is broken down into individual amino acids, which are then counted. This checks the overall composition and is one way of measuring how much peptide a sample actually contains.
NMR
Nuclear magnetic resonance gives structural information that other methods miss. It is used mainly for reference standards, where the identity of the material has to be established as firmly as possible.
When DSIP was first characterised in 1978, the authors reported that only the alpha-aspartyl form of the peptide was highly active, and its beta-aspartyl isomer was not. The two have identical mass. Telling them apart takes more than a mass check, which is exactly the gap orthogonal methods exist to close. The study is covered in our DSIP summary.
Where regulators are looking
Peptide quality testing is an active regulatory area. On 28 July 2026 the FDA published 17 revised draft product-specific guidances for generic peptide products. The agency said they update its recommendations in five areas, including impurity thresholds and higher order structure assessment, and it withdrew its May 2021 guidance on certain highly purified synthetic peptides as no longer reflecting its current scientific thinking.
Those guidances apply to generic drug applications, not to research materials. They do show the direction of travel: identity and impurities are being assessed in more depth, not less.
What analytical testing does not establish
- Identity is not activity. Analytical methods describe physical and chemical properties. They do not show that a peptide does anything in a biological system.
- Low-level variants can be missed. A minor sequence variant at very low abundance may escape detection if a method lacks sensitivity.
- Some isomers need targeted methods. Isobaric and chiral differences, such as leucine against isoleucine or the two forms of aspartate, need methods designed to separate them.
- A summary is only as good as its data. A certificate that reports results without the underlying chromatograms and spectra cannot be checked independently.
How we treat claims that go beyond the data is set out in how we write.
Orthogonal identification on a certificate of analysis
A certificate that relies on orthogonal identification shows it. These are the items that indicate identity was tested, not assumed.
- Identity confirmed by mass spectrometry, with the observed mass next to the calculated mass
- Mass accuracy stated, so the closeness of the match can be judged
- HPLC chromatogram attached, with individual impurity peaks listed
- Method details given: column, mobile phase, gradient and detection wavelength
- MS/MS or sequence coverage reported where the sequence has isobaric residues
- Peptide content or water content stated alongside purity
- Lot number on the certificate identical to the lot on the vial label
The first line matters most. A certificate showing only a purity percentage has measured how clean the sample is, not what it is.
- Orthogonal identification uses independent methods that measure different properties
- HPLC shows how clean a sample is, not which molecule it is
- Mass spectrometry confirms mass, and MS/MS supports the sequence
- Isobaric and isomeric residues can need additional targeted methods
- Analytical identity says nothing about biological activity
Frequently asked questions
Because retention time depends on the method as much as the molecule. Column, solvent, gradient and temperature all change it, and two different compounds can come off the column at nearly the same time under one set of conditions. It is useful as a comparison with a reference standard run on the same method, but it does not identify a molecule on its own.
It measures the mass of what is actually in the sample. If the observed mass matches the mass calculated from the sequence, that is strong evidence the right peptide is present. Mass shifts also reveal truncations, deletions and modifications that chromatography may not separate.
Yes. Molecules with the same mass, such as a peptide containing leucine and the same peptide containing isoleucine, give the same intact mass. Fragmentation methods like MS/MS, targeted chromatography or NMR may be needed to separate them, which is why reference standard work combines several methods.
Purity is the percentage of the chromatogram taken up by the main peak. Peptide content is the percentage of the weighed powder that is peptide at all, once water, salts and counter-ions are accounted for. A sample can show high purity and still contain a substantial share of non-peptide material by weight.
No. Orthogonal methods establish physical and chemical identity and purity. They say nothing about biological activity, potency or suitability for any use, which would need entirely separate functional studies.
See identity testing explained step by step
Members get HPLC chromatogram and mass spectrum walkthroughs that show how identity and purity are confirmed together.
- ✓Full VIP video and document library
- ✓Annotated COAs, research summaries and guides
- ✓New content added regularly
- ✓Approval-based members area
- McCarthy D, Han Y, Carrick K, Schmidt D, Workman W, Matejtschuk P, Duru C, Atouf F, 2023. Reference standards to support quality of synthetic peptide therapeutics. Pharmaceutical Research, 40, 1317 to 1328. DOI
- US Food and Drug Administration, 2026. FDA publishes revised draft product-specific guidances for certain generic peptide products. Drug alerts and statements, 28 July 2026. View source
- Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS, 2024. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, 1235, 124033. DOI
- Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M, 1978. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Archiv, 376, 119 to 129. DOI
- 16 Sep 2026: First published.
This article is general educational information about analytical chemistry and published research. It is not medical, legal or regulatory advice, and nothing in it describes or recommends the use of any compound in people or animals. Compounds discussed are for Research Use Only: not for human or veterinary use, not for diagnostic use, and not for use as a food, dietary supplement or cosmetic.
